- Home
- FOLD vs ALVO Comparison
FOLD vs ALVO Comparison
Compare FOLD & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- ALVO
- Stock Information
- Founded
- FOLD 2002
- ALVO 2013
- Country
- FOLD United States
- ALVO Luxembourg
- Employees
- FOLD N/A
- ALVO N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- ALVO Biotechnology: Pharmaceutical Preparations
- Sector
- FOLD Health Care
- ALVO Health Care
- Exchange
- FOLD Nasdaq
- ALVO Nasdaq
- Market Cap
- FOLD 2.9B
- ALVO 2.5B
- IPO Year
- FOLD 2007
- ALVO N/A
- Fundamental
- Price
- FOLD $7.58
- ALVO $8.07
- Analyst Decision
- FOLD Strong Buy
- ALVO
- Analyst Count
- FOLD 10
- ALVO 0
- Target Price
- FOLD $26.89
- ALVO N/A
- AVG Volume (30 Days)
- FOLD 3.8M
- ALVO 481.1K
- Earning Date
- FOLD 07-31-2025
- ALVO 08-13-2025
- Dividend Yield
- FOLD N/A
- ALVO N/A
- EPS Growth
- FOLD N/A
- ALVO N/A
- EPS
- FOLD N/A
- ALVO 0.22
- Revenue
- FOLD $571,160,000.00
- ALVO $562,478,000.00
- Revenue This Year
- FOLD $20.98
- ALVO $33.32
- Revenue Next Year
- FOLD $20.74
- ALVO $46.16
- P/E Ratio
- FOLD N/A
- ALVO $37.15
- Revenue Growth
- FOLD 25.35
- ALVO 82.19
- 52 Week Low
- FOLD $5.51
- ALVO $7.35
- 52 Week High
- FOLD $12.65
- ALVO $13.70
- Technical
- Relative Strength Index (RSI)
- FOLD 69.88
- ALVO 40.69
- Support Level
- FOLD $7.40
- ALVO $7.97
- Resistance Level
- FOLD $7.80
- ALVO $8.16
- Average True Range (ATR)
- FOLD 0.22
- ALVO 0.34
- MACD
- FOLD 0.01
- ALVO -0.04
- Stochastic Oscillator
- FOLD 87.61
- ALVO 17.03
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.